nafamostat has been researched along with gemcitabine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Sakamoto, T; Shiba, H; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
| Chiao, PJ; Gocho, T; Hirohara, S; Misawa, T; Uwagawa, T; Yanaga, K | 1 |
| Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| Fujiwara, Y; Furukawa, K; Gocho, T; Haruki, K; Iwase, R; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Fujiwara, Y; Furukawa, K; Haruki, K; Iwase, R; Misawa, T; Ohashi, T; Shiba, H; Uwagawa, T; Yanaga, K | 2 |
| Uwagawa, T; Yanaga, K | 1 |
| Fujiwara, Y; Futagawa, Y; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Haruki, K; Horiuchi, T; Iwase, R; Ohashi, T; Saito, N; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K | 1 |
| Furukawa, K; Gocho, T; Onda, S; Sakamoto, T; Shiba, H; Shiozaki, H; Uwagawa, T; Yanaga, K; Yasuda, J | 1 |
| Furukawa, K; Gocho, T; Hamura, R; Ikegami, T; Onda, S; Sakamoto, T; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K; Yasuda, J | 1 |
1 review(s) available for nafamostat and gemcitabine
| Article | Year |
|---|---|
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome | 2015 |
5 trial(s) available for nafamostat and gemcitabine
| Article | Year |
|---|---|
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Guanidines; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Molecular Structure; Pancreatic Neoplasms; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2012 |
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Exanthema; Female; Gemcitabine; Guanidines; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Postoperative Period; Treatment Outcome | 2021 |
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Male; Pancreatic Neoplasms; Treatment Outcome | 2022 |
6 other study(ies) available for nafamostat and gemcitabine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Topics: Animals; Antimetabolites, Antineoplastic; Benzamidines; Cell Cycle; Deoxycytidine; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Gemcitabine; Guanidines; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Ribonucleotide Reductases; Serine Proteinase Inhibitors; Tumor Cells, Cultured | 2009 |
Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
Topics: Adenoviridae; Analysis of Variance; Animals; Benzamidines; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Guanidines; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2013 |
Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzamidines; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gallbladder Neoplasms; Gemcitabine; Guanidines; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Serine Proteinase Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
Topics: Antimetabolites, Antineoplastic; Benzamidines; Deoxycytidine; Gemcitabine; Guanidines; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Silicates; Titanium; Tomography, X-Ray Computed | 2015 |
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Guanidines; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |